<DOC>
	<DOCNO>NCT00482313</DOCNO>
	<brief_summary>The purpose study evaluate efficacy effectiveness methylphenidate treatment ADHD Swedish adult male prison inmate diagnose ADHD .</brief_summary>
	<brief_title>Efficacy Effectiveness Methylphenidate Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>The purpose study evaluate efficacy Prolonged Release ( PR ) OROS methylphenidate fix dosage compare placebo , effectiveness flexible dosage Prolonged Release ( PR ) OROS methylphenidate Swedish adult male prison inmates attention-deficit hyperactivity disorder ( ADHD ) . An initial randomised , double-blind , placebo-controlled parallel group trial 5 week follow open-label extension maximum 47 week , comprise altogether 52 week treatment . A follow-up carry 12 36 month post-study , respectively .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Male , 1865 year , imprison Norrtalje Prison WURSscore 36 fulfil least 4 6 criterion ASRS Screener initial screen precede trial Can read understand Swedish well enough participate evaluation precede trial Diagnosis ADHD accord Diagnostic Statistical Manual Mental Diseases , Fourth Edition , ( DSMIV ) confirm neuropsychiatric assessment include structure diagnostic interview neuropsychological measurement . At least 14 month leave conditional release . Informed Consent Form participate study sign subject . Subject agrees take supply study drug treatment ADHD study Subject able comply study visit schedule willing able complete protocolspecified assessment . Healthy basis physical examination result blood biochemistry test . If result biochemistry test within normal reference range , subject may include investigator considers deviation clinically relevant . Known nonresponder methylphenidate . Known allergy hypersensitivity methylphenidate . Any clinically unstable psychiatric condition include , limited , acute mood disorder , bipolar disorder , acute OCD . A diagnosis substance use disorder ( abuse/dependence ) accord DSMIV criterion within 3 month prior screen evaluation study . Known mental retardation . Subjects history epileptic seizure , glaucoma , uncontrolled hypertension , angina pectoris , cardiac arrhythmias structural heart abnormality . Use monoamine oxidase inhibitor , fluoxetine , venlafaxine , reboxetine , duloxetine . Use alpha2receptor agonist , neuroleptic , theophylline , coumarin anticoagulant anticonvulsant . Liver renal insufficiency . Subjects hepatitis C without liver insufficiency donÂ´t exclude long liver enzymes follow study . Subjects suicidal . Lactose intolerance .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Prison</keyword>
	<keyword>Treatment</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Placebo Control</keyword>
	<keyword>Parallel Assignment</keyword>
	<keyword>Efficacy Study</keyword>
</DOC>